Scholarlink

Purpose <p>To evaluate longitudinal morphologic changes of the double-layer sign (DLS) on optical coherence tomography (OCT) in eyes with neovascular age-related macular degeneration (nAMD) presenting with exudative macular neovascularization (eMNV) undergoing anti-vascular endothelial growth factor (VEGF) therapy.</p> Methods <p>This retrospective study included 207 consecutive treatment-naïve eyes (207 patients) with nAMD presenting with eMNV and a DLS treated with intravitreal anti-VEGF injections and were followed for ≥ 12&#xa0;months. All eyes received 3 monthly loading injections followed by either treat-and-extend (TAE) or pro re nata (PRN) retreatment, per predefined criteria. DLS area, length, and height were measured at baseline, after loading, and 12&#xa0;months.</p> Results <p>All 207 eyes demonstrated significant reductions in mean (± standard deviation) DLS area, length, and height 1&#xa0;month after the third monthly injection (165 ± 188&#xa0;µm<sup>2</sup>, 1446 ± 639&#xa0;µm, and 202 ± 109&#xa0;µm, respectively) compared with baseline (302 ± 264&#xa0;µm<sup>2</sup>, 1801 ± 573&#xa0;µm, and 282 ± 150&#xa0;µm, respectively) (<i>P</i> = 0.001, <i>P</i> = 0.001, and <i>P</i> = 0.024, respectively). At 12&#xa0;months the mean change in DLS area was −&#xa0;141&#xa0;µm<sup>2</sup> [95% confidence interval (CI) −&#xa0;185&#xa0;to −&#xa0;98], and median (95% CI) injection number was 8.1 (7.9 to 8.4). Eyes with subretinal and/or intraretinal fluid (SRF/IRF) at 12&#xa0;months showed re-enlargement of DLS parameters, whereas eyes without SRF/IRF maintained the post-treatment decrease.</p> Conclusion <p>DLS morphology regresses after anti-VEGF therapy, and persistent or recurrent fluid is associated with less durable regression. The DLS regresses in response to anti-VEGF therapy, and its behaviour correlates with the clinical course of exudative MNV associated with a DLS. DLS monitoring may complement-but not replace-multimodal imaging when assessing MNV activity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Morphologic changes of the double‐layer sign during anti-vascular endothelial growth factor therapy in eyes with neovascular age-related macular degeneration

  • 期刊论文

  • 发表日期：

    2025年8月28日

查看全文
  • Taiichi Hikichi,
  • Haruka Kurabe,
  • Amane Notoya,
  • Yuuna Oguro,
  • Misaki Hirano,
  • Yumeka Doi

摘要

Purpose

To evaluate longitudinal morphologic changes of the double-layer sign (DLS) on optical coherence tomography (OCT) in eyes with neovascular age-related macular degeneration (nAMD) presenting with exudative macular neovascularization (eMNV) undergoing anti-vascular endothelial growth factor (VEGF) therapy.

Methods

This retrospective study included 207 consecutive treatment-naïve eyes (207 patients) with nAMD presenting with eMNV and a DLS treated with intravitreal anti-VEGF injections and were followed for ≥ 12 months. All eyes received 3 monthly loading injections followed by either treat-and-extend (TAE) or pro re nata (PRN) retreatment, per predefined criteria. DLS area, length, and height were measured at baseline, after loading, and 12 months.

Results

All 207 eyes demonstrated significant reductions in mean (± standard deviation) DLS area, length, and height 1 month after the third monthly injection (165 ± 188 µm2, 1446 ± 639 µm, and 202 ± 109 µm, respectively) compared with baseline (302 ± 264 µm2, 1801 ± 573 µm, and 282 ± 150 µm, respectively) (P = 0.001, P = 0.001, and P = 0.024, respectively). At 12 months the mean change in DLS area was − 141 µm2 [95% confidence interval (CI) − 185 to − 98], and median (95% CI) injection number was 8.1 (7.9 to 8.4). Eyes with subretinal and/or intraretinal fluid (SRF/IRF) at 12 months showed re-enlargement of DLS parameters, whereas eyes without SRF/IRF maintained the post-treatment decrease.

Conclusion

DLS morphology regresses after anti-VEGF therapy, and persistent or recurrent fluid is associated with less durable regression. The DLS regresses in response to anti-VEGF therapy, and its behaviour correlates with the clinical course of exudative MNV associated with a DLS. DLS monitoring may complement-but not replace-multimodal imaging when assessing MNV activity.